Author: syreetadasilva
Japan – Eisai: Economic Arrangements of Amendment to Alzheimer’s Disease Treatment Collaboration Agreement with Biogen
Eisai Co., Ltd. announced the following economic arrangements agreed in the amendment to Alzheimer’s disease collaboration agreement with Biogen Inc. separately announced today. Effective as of January 1, 2023, Eisai will receive a tiered royalty on net sales of ADUHELM rather than sharing global profits and losses. The details of the royalty rates are shown in the table below. Economic arrangements for 2022 will remain materially unchanged with Eisai’s share of ADUHELM expenses capped at $335 million for the costs related to development, commercialization and manufacturing for the period from January 1, 2022, to December 31, 2022. In regards to ... Read more